Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00068549 · ClinicalTrials.gov registry record · Phase 1

Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

A Phase 1 study, sponsored by Gynecologic Oncology Group.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target

NCT00068549: Completed Phase 1 study, sponsored by Gynecologic Oncology Group.

NCT00068549 is a Phase 1 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00068549, a Phase 1 study, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target

Study Summary

This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy and cisplatin in treating patients with cervical cancer that has not spread beyond the pelvis. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining cisplatin with gemcitabine may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells.

Interventions

  • DRUG Cisplatin
  • RADIATION Radiation Therapy
  • DRUG Gemcitabine Hydrochloride
  • RADIATION Internal Radiation Therapy

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2003-10
Phase Phase 1
Gynecologic Oncology Group

154 total trials

What the finished NCT00068549 record still lists

NCT00068549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.

NCT00068549 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00068549 about?

NCT00068549 is a clinical study titled "Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer". This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy and cisplatin in treating patients with cervical cancer that has not spread beyond the pelvis. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemot...

What is the current status of trial NCT00068549?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2003-10.

What interventions are being tested in trial NCT00068549?

The interventions under investigation include: Cisplatin (DRUG), Radiation Therapy (RADIATION), Gemcitabine Hydrochloride (DRUG), Internal Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT00068549?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00068549's enrollment target sits among peer trials

13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00068549, the US trial registry maintained by the National Library of Medicine. NCT00068549 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.